Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-11 of 11

Sort by

Sort Order Select

Journal Articles

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

Akihiko Shimomura, Noboru Yamamoto, Shunsuke Kondo, Yutaka Fujiwara, Shigenobu Suzuki, Noriko Yanagitani, Atsushi Horiike, Satoru Kitazono, Fumiyoshi Ohyanagi, Toshihiko Doi, Yasutoshi Kuboki, Akihito Kawazoe, Kohei Shitara, Izumi Ohno, Udai Banerji, Raghav Sundar, Shuichi Ohkubo, Elizabeth M. Calleja, Makoto Nishio

Mol Cancer Ther (2019) 18 (3): 531–540.

https://doi.org/10.1158/1535-7163.MCT-18-0831

Published: 01 March 2019

View article titled, First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

Journal Articles

Abstract A204: INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)

Yutaka Fujiwara, Kohei Shitara, Toshio Shimizu, Kan Yonemori, Nobuaki Matsubara, Izumi Ohno, Takahiro Kogawa, Yoichi Naito, Lance Leopold, Kahori Sasahara, Naoyoshi Yatsuzuka, Tomoko Takami, Takashi Shimamoto, Noboru Yamamoto, Toshihiko Doi

Mol Cancer Ther (2018) 17 (1_Supplement): A204.

https://doi.org/10.1158/1535-7163.TARG-17-A204

Published: 01 January 2018

View article titled, Abstract A204: INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)

Journal Articles

Abstract B160: First-in-human phase 1 study of E7090, a novel selective inhibitor of FGFRs, in patients with advanced solid tumors

Takafumi Koyama, Toshio Shimizu, Satoru Iwasa, Yutaka Fujiwara, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Akihiko Shimomura, Sakura Iizumi, Tatsuya Sasaki, Junji Furuse, Noboru Yamamoto

Mol Cancer Ther (2018) 17 (1_Supplement): B160.

https://doi.org/10.1158/1535-7163.TARG-17-B160

Published: 01 January 2018

View article titled, Abstract B160: First-in-human phase 1 study of E7090, a novel selective inhibitor of FGFRs, in patients with advanced solid tumors

Journal Articles

Abstract B87: First-in-human phase I dose escalation study of TAS-116, a novel, orally active HSP90α and HSP90β selective inhibitor, in patients with advanced solid tumors

Akihiko Shimomura, Atsushi Horiike, Yuichi Tambo, Fumiyoshi Ohyanagi, Noriko Yanagitani, Satoru Kitazono, Yutaka Fujiwara, Yuko Tanabe, Shuichi Ohkubo, Noboru Yamamoto, Makoto Nishio

Mol Cancer Ther (2015) 14 (12_Supplement_2): B87.

https://doi.org/10.1158/1535-7163.TARG-15-B87

Published: 01 December 2015

View article titled, Abstract B87: First-in-human phase I dose escalation study of TAS-116, a novel, orally active HSP90α and HSP90β selective inhibitor, in patients with advanced solid tumors

Journal Articles

Abstract C95: Reversibility of acquired resistance and “addiction” to MET inhibitors.

Yohei Funakoshi, Toru Mukohara, Hideo Tomioka, Roudy Chiminch Ekyalongo, Yu Kataoka, Yohei Shimono, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Yutaka Fujiwara, Hironobu Minami

Mol Cancer Ther (2013) 12 (11_Supplement): C95.

https://doi.org/10.1158/1535-7163.TARG-13-C95

Published: 01 November 2013

View article titled, Abstract C95: Reversibility of acquired resistance and “addiction” to MET inhibitors.

Journal Articles

Abstract C68: Phase I study of administration of LY2523355, an Eg5 inhibitor, for 3 consecutive days every 3 weeks in Japanese patients with refractory solid tumors.

Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Yasuhide Yamada, Hiroshi Wakui, Shinji Nakamichi, Hidenori Mizugaki, Satoru Kitazono, Hironori Kanda, Kohei Suzuki, Shiro Akinaga, Tomohide Tamura

Mol Cancer Ther (2013) 12 (11_Supplement): C68.

https://doi.org/10.1158/1535-7163.TARG-13-C68

Published: 01 November 2013

View article titled, Abstract C68: Phase I study of administration of LY2523355, an Eg5 inhibitor, for 3 consecutive days every 3 weeks in Japanese patients with refractory solid tumors.

Journal Articles

Abstract A167: A phase I study of single-agent BEZ235 (SDS sachet), once- or twice-daily, in Japanese patients with advanced solid tumors.

Koichiro Watanabe, Hironobu Minami, Satoshi Otsu, Yoshinori Hirashima, Ryotaro Morinaga, Kazuo Nishikawa, Yasushi Hisamatsu, Toru Mukohara, Naomi Kiyota, Naoko Chayahara, Masanori Toyoda, Yoshinori Imamura, Yutaka Fujiwara, Cornelia Quadt, Matthew Robson, Kazuto Natsume, Takuji Aoki, Kuniaki Shirao

Mol Cancer Ther (2013) 12 (11_Supplement): A167.

https://doi.org/10.1158/1535-7163.TARG-13-A167

Published: 01 November 2013

View article titled, Abstract A167: A phase I study of single-agent BEZ235 (SDS sachet), once- or twice-daily, in Japanese patients with advanced solid tumors.

Journal Articles

Abstract C186: Tyro3 is a potential target for the treatment of breast cancer.

Roudy Chiminch Ekyalongo, Toru Mukohara, Yohei Funakoshi, Hideo Tomioka, Yu Kataoka, Yohei Shimono, Masanori Toyoda, Naomi Kiyota, Yutaka Fujiwara, Hironobu Minami

Mol Cancer Ther (2013) 12 (11_Supplement): C186.

https://doi.org/10.1158/1535-7163.TARG-13-C186

Published: 01 November 2013

View article titled, Abstract C186: Tyro3 is a potential target for the treatment of breast cancer.

Journal Articles

Abstract A260: A phase 1 study of sorafenib (BAY 43‐9006) in combination with S‐1 plus cisplatin in patients with advanced gastric cancer

Yasuhide Yamada, Hironobu Minami, Nozomu Fuse, Atsushi Ohtsu, Ken Kato, Naomi Kiyota, Yasushiro Shimada, Toshihiko Doi, Takako Nakajima, Tetsuya Hamaguchi, Yutaka Fujiwara, Yuichiro Ito, Kiyomi Mera

Mol Cancer Ther (2009) 8 (12_Supplement): A260.

https://doi.org/10.1158/1535-7163.TARG-09-A260

Published: 10 December 2009

View article titled, Abstract A260: A phase 1 study of sorafenib (BAY 43‐9006) in combination with S‐1 plus cisplatin in patients with advanced gastric cancer

Journal Articles

Abstract B15: Effect of axitinib (AG‐013736) on thyroid function and biomarkers: Results from phase I studies in Japanese patients

Yutaka Fujiwara, Naomi Kiyota, Naoko Chayahara, Akiyuki Suzuki, Yoshiko Umeyama, Toru Mukohara, Hironobu Minami

Mol Cancer Ther (2009) 8 (12_Supplement): B15.

https://doi.org/10.1158/1535-7163.TARG-09-B15

Published: 10 December 2009

View article titled, Abstract B15: Effect of axitinib (AG‐013736) on thyroid function and biomarkers: Results from phase I studies in Japanese patients

Journal Articles

Phase I study of cediranib, an oral, highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

Noboru Yamamoto, Yasuhide Yamada, Kazuhiko Yamada, Hiroshi Nokihara, Yutaka Fujiwara, Taizo Hirata, Nobuyuki Yamamoto, Narikazu Boku, Eisei Shin, Tomohide Tamura

Mol Cancer Ther (2007) 6 (11_Supplement): A253.

Published: 01 November 2007

View article titled, Phase I study of cediranib, an oral, highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

NARROW

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

Abstract A204: INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)

Abstract B160: First-in-human phase 1 study of E7090, a novel selective inhibitor of FGFRs, in patients with advanced solid tumors

Abstract B87: First-in-human phase I dose escalation study of TAS-116, a novel, orally active HSP90α and HSP90β selective inhibitor, in patients with advanced solid tumors

Abstract C95: Reversibility of acquired resistance and “addiction” to MET inhibitors.

Abstract C68: Phase I study of administration of LY2523355, an Eg5 inhibitor, for 3 consecutive days every 3 weeks in Japanese patients with refractory solid tumors.

Abstract A167: A phase I study of single-agent BEZ235 (SDS sachet), once- or twice-daily, in Japanese patients with advanced solid tumors.

Abstract C186: Tyro3 is a potential target for the treatment of breast cancer.

Abstract A260: A phase 1 study of sorafenib (BAY 43‐9006) in combination with S‐1 plus cisplatin in patients with advanced gastric cancer

Abstract B15: Effect of axitinib (AG‐013736) on thyroid function and biomarkers: Results from phase I studies in Japanese patients

Phase I study of cediranib, an oral, highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only